Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec;81(8):1304–1310. doi: 10.1038/sj.bjc.6694384

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines

U Vanhoefer 1, M R Müller 1, R A Hilger 1, B Lindtner 1, U Klaassen 1, N Schleucher 1, Y M Rustum 2, S Seeber 1
PMCID: PMC2362978  PMID: 10604726

Abstract

Recent data suggest that expression of the membrane P170-glycoprotein (P-gp) may confer resistance to the topoisomerase- I-interactive agent topotecan. The present study describes the cellular effects of a new dihydropyridine analogue, PAK-200S, on P-gp-mediated resistance to topotecan in human breast and ovarian tumour cells. PAK-200S at a non-cytotoxic concentration of 2.0 μM completely reversed resistance to topotecan in P-gp-expressing MCF-7/adr (breast) and A2780/Dx5 (ovarian) tumour cells, respectively, with no effects on parental cells. Cellular pharmacokinetic studies by reversed-phase high-performance liquid chromatography analysis showed significantly lower cellular drug concentrations of the pharmacologically active closed-ring lactone of topotecan in multidrug-resistant cells than in parental cells. PAK-200S was effective in restoring the cellular lactone concentrations of topotecan in resistant MCF-7/adr cells to levels comparable to those obtained in parental cells. Furthermore, exposure of MCF-7/adr cells to topotecan in the presence of PAK-200S significantly increased the induction of protein-linked DNA breaks. PAK-200S did not alter nuclear topoisomerase I-mediated ex vivo pBR322 DNA plasmid unwinding activity and topoisomerase-I protein expression. These results suggest that reversal of P-gp-mediated resistance to topotecan by PAK-200S was related to the restoration of cellular drug concentrations of the active lactone form of topotecan rather than a direct effect on topoisomerase-I function. © 1999 Cancer Research Campaign

Keywords: topotecan, PAK-200S, multidrug resistance, breast cancer, ovarian cancer

Full Text

The Full Text of this article is available as a PDF (137.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., Okada K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5565–5569. doi: 10.1073/pnas.84.16.5565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beijnen J. H., Smith B. R., Keijer W. J., van Gijn R., ten Bokkel Huinink W. W., Vlasveld L. T., Rodenhuis S., Underberg W. J. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal. 1990;8(8-12):789–794. doi: 10.1016/0731-7085(90)80122-6. [DOI] [PubMed] [Google Scholar]
  3. Benedetti P., Fiorani P., Capuani L., Wang J. C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res. 1993 Sep 15;53(18):4343–4348. [PubMed] [Google Scholar]
  4. Chen A. Y., Liu L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 1994;34:191–218. doi: 10.1146/annurev.pa.34.040194.001203. [DOI] [PubMed] [Google Scholar]
  5. Covey J. M., Jaxel C., Kohn K. W., Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 1989 Sep 15;49(18):5016–5022. [PubMed] [Google Scholar]
  6. D'Arpa P., Machlin P. S., Ratrie H., 3rd, Rothfield N. F., Cleveland D. W., Earnshaw W. C. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2543–2547. doi: 10.1073/pnas.85.8.2543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Danks M. K., Schmidt C. A., Cirtain M. C., Suttle D. P., Beck W. T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 1988 Nov 29;27(24):8861–8869. doi: 10.1021/bi00424a026. [DOI] [PubMed] [Google Scholar]
  8. Eng W. K., McCabe F. L., Tan K. B., Mattern M. R., Hofmann G. A., Woessner R. D., Hertzberg R. P., Johnson R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol. 1990 Oct;38(4):471–480. [PubMed] [Google Scholar]
  9. Fairchild C. R., Ivy S. P., Kao-Shan C. S., Whang-Peng J., Rosen N., Israel M. A., Melera P. W., Cowan K. H., Goldsmith M. E. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res. 1987 Oct 1;47(19):5141–5148. [PubMed] [Google Scholar]
  10. Friedman H. S., Dolan M. E., Kaufmann S. H., Colvin O. M., Griffith O. W., Moschel R. C., Schold S. C., Bigner D. D., Ali-Osman F. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Cancer Res. 1994 Jul 1;54(13):3487–3493. [PubMed] [Google Scholar]
  11. Grochow L. B., Rowinsky E. K., Johnson R., Ludeman S., Kaufmann S. H., McCabe F. L., Smith B. R., Hurowitz L., DeLisa A., Donehower R. C. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos. 1992 Sep-Oct;20(5):706–713. [PubMed] [Google Scholar]
  12. Gromova I. I., Kjeldsen E., Svejstrup J. Q., Alsner J., Christiansen K., Westergaard O. Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. Nucleic Acids Res. 1993 Feb 11;21(3):593–600. doi: 10.1093/nar/21.3.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hendricks C. B., Rowinsky E. K., Grochow L. B., Donehower R. C., Kaufmann S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 1992 Apr 15;52(8):2268–2278. [PubMed] [Google Scholar]
  14. Hoki Y., Fujimori A., Pommier Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol. 1997;40(5):433–438. doi: 10.1007/s002800050682. [DOI] [PubMed] [Google Scholar]
  15. Holm C., Covey J. M., Kerrigan D., Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 1989 Nov 15;49(22):6365–6368. [PubMed] [Google Scholar]
  16. Hsiang Y. H., Lihou M. G., Liu L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989 Sep 15;49(18):5077–5082. [PubMed] [Google Scholar]
  17. Hsiang Y. H., Liu L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988 Apr 1;48(7):1722–1726. [PubMed] [Google Scholar]
  18. Jansen W. J., Hulscher T. M., van Ark-Otte J., Giaccone G., Pinedo H. M., Boven E. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer. 1998;77(3):359–365. doi: 10.1038/bjc.1998.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jonsson E., Fridborg H., Csóka K., Dhar S., Sundström C., Nygren P., Larsson R. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer. 1997;76(2):211–219. doi: 10.1038/bjc.1997.364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kanzawa F., Sugimoto Y., Minato K., Kasahara K., Bungo M., Nakagawa K., Fujiwara Y., Liu L. F., Saijo N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 1990 Sep 15;50(18):5919–5924. [PubMed] [Google Scholar]
  21. Kapoor R., Slade D. L., Fujimori A., Pommier Y., Harker W. G. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res. 1995;7(2):83–95. [PubMed] [Google Scholar]
  22. Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351–375. doi: 10.1146/annurev.bi.58.070189.002031. [DOI] [PubMed] [Google Scholar]
  23. Ma J., Maliepaard M., Nooter K., Loos W. J., Kolker H. J., Verweij J., Stoter G., Schellens J. H. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer. 1998 May;77(10):1645–1652. doi: 10.1038/bjc.1998.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mattern M. R., Hofmann G. A., Polsky R. M., Funk L. R., McCabe F. L., Johnson R. K. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res. 1993;5(12):467–474. [PubMed] [Google Scholar]
  25. Minderman H., Vanhoefer U., Toth K., Minderman M. D., Rustum Y. M. A unique human ovarian carcinoma cell line expressing CD34 in association with selection for multidrug resistance. Cancer. 1996 Dec 1;78(11):2427–2436. [PubMed] [Google Scholar]
  26. Müller M. R., Lennartz K., Nowrousian M. R., Dux R., Tsuruo T., Rajewsky M. F., Seeber S. Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysis. Cytometry. 1994 Jan 1;15(1):64–72. doi: 10.1002/cyto.990150111. [DOI] [PubMed] [Google Scholar]
  27. Niwa K., Yamada K., Furukawa T., Shudo N., Seto K., Matsumoto T., Takao S., Akiyama S., Shimazu H. Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo- 1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3 -pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin. Cancer Res. 1992 Jul 1;52(13):3655–3660. [PubMed] [Google Scholar]
  28. Pommier Y. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol. 1996 Feb;23(1 Suppl 3):3–10. [PubMed] [Google Scholar]
  29. Ryan A. J., Squires S., Strutt H. L., Evans A., Johnson R. T. Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells. Carcinogenesis. 1994 May;15(5):823–828. doi: 10.1093/carcin/15.5.823. [DOI] [PubMed] [Google Scholar]
  30. Ryan A. J., Squires S., Strutt H. L., Johnson R. T. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res. 1991 Jun 25;19(12):3295–3300. doi: 10.1093/nar/19.12.3295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sandler D. P., Ross J. A. Epidemiology of acute leukemia in children and adults. Semin Oncol. 1997 Feb;24(1):3–16. [PubMed] [Google Scholar]
  32. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  33. Slichenmyer W. J., Rowinsky E. K., Donehower R. C., Kaufmann S. H. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993 Feb 17;85(4):271–291. doi: 10.1093/jnci/85.4.271. [DOI] [PubMed] [Google Scholar]
  34. Sorensen M., Sehested M., Jensen P. B. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer. 1995 Aug;72(2):399–404. doi: 10.1038/bjc.1995.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sugimoto Y., Tsukahara S., Oh-hara T., Isoe T., Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 1990 Nov 1;50(21):6925–6930. [PubMed] [Google Scholar]
  36. Sugimoto Y., Tsukahara S., Oh-hara T., Liu L. F., Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. 1990 Dec 15;50(24):7962–7965. [PubMed] [Google Scholar]
  37. Tan K. B., Mattern M. R., Eng W. K., McCabe F. L., Johnson R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst. 1989 Nov 15;81(22):1732–1735. doi: 10.1093/jnci/81.22.1732. [DOI] [PubMed] [Google Scholar]
  38. Trask D. K., DiDonato J. A., Muller M. T. Rapid detection and isolation of covalent DNA/protein complexes: application to topoisomerase I and II. EMBO J. 1984 Mar;3(3):671–676. doi: 10.1002/j.1460-2075.1984.tb01865.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tsao Y. P., Russo A., Nyamuswa G., Silber R., Liu L. F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 1993 Dec 15;53(24):5908–5914. [PubMed] [Google Scholar]
  40. Uemura T., Yanagida M. Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J. 1984 Aug;3(8):1737–1744. doi: 10.1002/j.1460-2075.1984.tb02040.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Vanhoefer U., Cao S., Minderman H., Tóth K., Scheper R. J., Slovak M. L., Rustum Y. M. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res. 1996 Feb;2(2):369–377. [PubMed] [Google Scholar]
  42. Vanhoefer U., Voigt W., Hilger R. A., Yin M. B., Harstrick A., Seeber S., Rustum Y. M. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. Oncol Res. 1997;9(9):485–494. [PubMed] [Google Scholar]
  43. Yang C. J., Horton J. K., Cowan K. H., Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. 1995 Sep 15;55(18):4004–4009. [PubMed] [Google Scholar]
  44. Yang L., Wold M. S., Li J. J., Kelly T. J., Liu L. F. Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. Proc Natl Acad Sci U S A. 1987 Feb;84(4):950–954. doi: 10.1073/pnas.84.4.950. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES